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Highlights 
• Bidirectional glutamatergic communication between neurons and astrocytes during post-
natal development are poorly understood 
• mGlu5-mediated signalling may be important for developmental maturation of astrocytes  
• Astrocyte maturation may be important for a proper neuronal development 
 
 
Abstract 
Astrocytes, the largest glial population in human and murine brains, are crucial to the regulation 
of synaptic connectivity. During the first three weeks of post-natal development, immature 
astrocytes express mGlu5 and expands several fold while undergoing a transition towards their 
mature phase. Although mGlu5-mediated signalling in astrocyte functions has been extensively 
studied in the last decades, whether this signalling is implicated in the mechanisms governing their 
development, as well as the effects of dysregulated astrocytic development on neurodevelopmental 
disorders, are still unclear. The aim of this review is to examine what is known about the mGlu5-
mediated signalling in the developing astrocytes and its possible contribution to the 
pathophysiology of autism spectrum disorders.  
 
 
 
 
Overview 
Mature astrocytes are integral components of the “tripartite synapse” [1] in which perisynaptic 
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astrocyte processes regulate neurotransmitter homeostasis and recycling, provide basic substrates 
for neuronal metabolism, sequester ions, promote synaptogenesis and synaptic remodelling, and 
modulate synaptic activity and plasticity [2,3]. Immature astrocytes express high levels of 
metabotropic glutamate receptor 5 (mGlu5) [4] and with their numerous small peri-synaptic 
processes are in strategic position to monitor and, eventually, influence developing synaptic 
activity. Number of studies in the last decades established a bidirectional glutamatergic 
communication between neurons and astrocytes [2,5]. The interaction of synaptically released 
glutamate with G-protein-coupled receptors (GPCRs) in astrocytes, in particular with group I 
mGlu, leads to transient elevations of intracellular calcium (Ca2+) levels [6,7,8] which have been 
linked to the release of neuroactive substances called gliotransmitters [2] that in turn can modulate 
diverse physiological phenomena [9,10], including synaptic transmission and plasticity [5].  
Despite the putative importance of mGlu5-mediated signalling on post-natal maturation of 
astrocytes and the associated synapses, surprisingly little is known about this astrocytic signalling 
on the cellular and molecular mechanisms regulating post-natal maturation phase of astrocytes and 
the associated neuronal circuits.  
Excellent reviews have recently explored the role of astrocyte-secreted or –expressed factors on 
the formation and maturation of synaptic circuits [*11,12,13,14], therefore in this review we intend 
to examine what is known about the glutamatergic signalling on developing astrocytes and to 
discuss the involvement of this signalling in the pathophysiology of autism.  
 
mGlu5-mediated signalling in the post-natal developmental of astrocytes 
Even though peak gliogenesis occurs about E17-18 [15], astrocytes are mainly generated during 
the post-natal period, when they expand 6-8 fold [16, 17]. A recent study has shown that the local 
proliferation of already differentiated astrocytes is the major source of astroglia in post-natal cortex 
[16]. The fact that early astrocytes continue to divide while differentiating and maturing during the 
second and the third post-natal week implies that they may have progenitor status and, during the 
first three post-natal weeks of their maturation, they undergo dramatic molecular and structural 
changes (Fig 1). For example, genes regulating proliferation such as MKI67 are progressively 
down-regulated whereas a number of important astroglial genes, including those coding for 
glutamate transporter GLT1, GABA transporters (GATs), connexin 30 and 43 (Cx30 and Cx43) 
and the inwardly rectifying potassium channel Kir4.1, are progressively up-regulated [18,**19]. 
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These astroglial genes represent some of most characteristic and important functions of astrocytes 
in the central nervous system (CNS): GATs and GLT1 are crucial for maintaining the proper 
termination of GABA or glutamate signalling at synapses, and Kir1.4 is critical for maintaining 
the K+ gradient for glutamate uptake and buffering activity-dependent K+ release. The induction 
of these genes during post-natal development suggests that astrocytes undergo developmental 
maturation from the first week to the second and third weeks after birth.  
The genes that are developmentally regulated in immature astrocytes also include those controlling 
glutamatergic signalling. The expression of GRM5 and Homer1 genes, which respectively encode 
metabotropic glutamate receptor 5 (mGlu5) and the Homer1 scaffold proteins, is high in 
developing astrocytes during the first post-natal week but have dramatically decreased by the third 
[18,**19,4]. It has recently been found that Homer1 proteins modulate mGlu5 calcium (Ca2+) 
signalling in developing astrocytes [*20]. Given the close association of astrocytes with synapses 
from the early post-natal phase, the expression pattern of mGlu5 Ca2+ signalling indicates that 
developing astrocytes sense neuronal activity during their post-natal maturation. This is 
particularly intriguing because it indicates that astrocytes can detect neuronal activity even before 
the major wave of synaptogenesis occurs (i.e. during second and third post-natal week), and 
suggests that the activity-dependent induction of astroglial genes may take place from the early 
stages of post-natal development. The importance of synaptically released glutamate in the post-
natal maturation of astrocytes is not clear, but several papers have shown that neuronal activity has 
an important role in the regulation of astrocyte morphology [21], specification [22] and function 
[23]. For example neurons can induce the classic stellate morphology in astrocytes, resembling 
their appearance in vivo [21] and neuron-derived Notch signalling is necessary and sufficient to 
promote the expression of several plasma membrane transporters, including GLT1 [23]. Many of 
these results have been obtained in cultured cells and the cellular mechanisms by which early 
formed synapses signal to immature astrocytes to regulate their development in vivo remain, 
however, poorly understood. 
 
The role of mGlu5-mediated signaling on the post-natal maturation phase of astrocytes, at the 
moment, has never been investigated. Interestingly, Homer1 proteins have been recently found to 
modulate the mGlu5 Ca2+ signalling in cortical astrocytes since the second post-natal week [*20]. 
The long form Homer 1b/c is constitutively expressed in immature astrocytes; its 
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immunoreactivity is visible in the soma and main processes as well as in the perivascular end feet 
of astrocytes, emphasizing the widespread distribution of this scaffold protein across cellular 
compartments. At the subcellular levels Homer1b/c has a punctate distribution and clusters with 
mGlu5 and endoplasmic reticulum (ER) tubules to form sub-plasmalemmal microdomains. Ca2+ 
events in astrocytes may occur both in the form of global cytoplasmic increase and of local events 
along astrocytic processes [24,25] and the expression of Homer1b/c in astrocytic processes 
facilitates both [*20]. Indeed, when Homer1b/c is replaced by the short form Homer1a, the 
physical link between mGlu5 and ER is lost and the drop in localized events leads to a strong 
reduction of global cytosolic Ca2+ signalling [*20]. Regulation of the global levels of Ca2+ by 
Homer1 proteins may have a crucial importance in developing cells where cytosolic Ca2+ signaling 
plays a key role in the regulation of both proliferation and differentiation [23].  
The existence of localized Ca2+ events in astrocytic process suggests the presence of a subcellular 
specialization controlling the spread of cytosolic Ca2+ within individual astrocytic compartments. 
Electron microscopy studies have indeed indicated that astrocyte architecture is characterized by 
the prevalence of processes containing ER tubules and mitochondria [25,2]. This architecture 
could favour the organization of subcellular structural domains where the close interaction among 
ER and mitochondria may have a crucial role in the modulation of cytosolic Ca2+ signals or in the 
regulation of mitochondrial activities, as already reported in a number of cells including neurons 
[26]. Given that mitochondrial Ca2+ handling through the mitochondrial Ca2+ uniporter (MCU) can 
impact diverse aspects of cellular physiology including mitochondrial metabolism [26, 27, 28] and 
the expression of MCU gene is particularly high in immature astrocytes [**19], investigate the 
role of MCU in the modulation of astrocytic Ca2+ signals would be an important next step to 
understand the role of mGlu5-mediated Ca2+ signaling in the post-natal maturation of astrocytes. 
The gene of fragile mental retardation 1 (FMR1), which encodes the fragile X mental retardation 
protein (FMRP) [29], is also part of group I mGlu signalling. Like mGlu5 and Homer1, FMR1 is 
highly expressed in the first post-natal week but its expression decreases over the next two weeks. 
It has been reported that FMR1 has many physiological functions, including the control of local 
protein translation [30]. Accumulating evidence suggests that it plays a  central role in regulating 
GLT1 expression in developing astrocytes [31], thus indicating that it also plays a role in post-
natal astrocyte maturation. The functional role of GLT1 transporter occurs at perisynaptic 
processes of astrocytes. Developing astrocytes sprout cellular processes during the first week of 
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postnatal development, and most processes appear filopodial (i.e. actively growing) in nature. 
At this developmental time, astrocyte borders are quite ragged and long processes extend well 
beyond them but, during subsequent weeks, the developing processes become ramified and there 
is an increasing formation of fine distal processes [32], also known as peripheral astrocyte 
processes (PAPs) [33], which express a number of proteins including plasma membrane 
transporters. Although a significant number of astrocytes are generated during the first post-natal 
week, PAPs are not induced in until several weeks later, thus suggesting that a sort of 
morphological maturation also occurs during the first 3-4 postnatal weeks. As perisynaptic 
processes are responsive to neural activity, it is likely that synaptic activity drives the 
morphological development of astroglial PAPs towards newly-formed synaptic contacts, although 
the role of neuronal activity in the formation and modulation of PAPs in developing astrocytes has 
never been investigated directly. Indeed, the synapse association of astrocytic peri-synaptic 
processes is known to be a dynamic process that can be altered by neuronal activity [34,35,36] 
and, in agreement with this possibility, astrocyte coverage of synaptic contacts is altered during 
development, in response to injury and in various physiological conditions, such as partition, 
starvation, and satiety [*11,37,38]. Most of these structural changes occur over a slow timescale, 
and it is likely that the cue for altered astrocyte-synapse interaction is a direct sensing of alterations 
in neuronal activity rather than an additional signal released by neurons. Despite, these indications, 
the role of glutamatergic signalling in the formation and modulation of PAPs in developing 
astrocytes, however, has never been investigated directly. A recent study of the role of Cx30 in 
modulating behavioural and cognitive processes has proposed a new role for this channel in the 
modulation of glutamate signalling and astrocyte morphogenesis. Cx30 is one of the two main 
astroglial gap-junction subunits, and seems to control excitatory synaptic transmission through 
modulation of astroglial glutamate transport, which directly laters synaptic activity [*39]. 
However, unexpectedly, the role of Cx30 in modulating glutamate transport is mediated by its 
ability of keeping astrocytic PAPs restricted to perisynaptic regions and is independent of its 
channel function. Cx30 seems indeed to be very similar to that of a cell adhesion protein. Thus, by 
controlling the migration of processes towards the clefts of developing excitatory synapses, Cx30 
regulates the efficacy of glutamate transport and, consequently, the strength of excitatory synapses.  
 
Possible involvement of post-natal astrocytes in the pathogenesis of autism spectrum 
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disorders 
Over the last ten years, growing evidence has emerged to suggest that astrocytes may play an 
important role in the pathophysiology of autism spectrum disorders (ASDs) [40]. The genes 
associated with ASDs are highly expressed during development [41] and many of those whose 
variation confers susceptibility to ASDs play a fundamental role in brain development [42]. 
Unfortunately, there is still a lack of detailed molecular studies of developmental events within the 
brain areas involved in the etiology of ASDs, and very little is known about the characteristics of 
astrocytes in ASDs, although recent transcriptome analyses have indicated that they contain many 
of the genes associated with ASDs [18,**19].  
As mentioned above, developing astrocytes highly express mGlu5 signalling, a pathway that plays 
an important roles in normal brain development and in disorders such as Phelan-McDermid 
syndrome [43], fragile X syndrome [44] and some other isolated ASDs [45]. In neurons and 
developing astrocytes, the mGlu5 Ca2+ signalling generated by inositol 1,4,5-trisphosphate 
receptor (IP3R) is regulated by the expression of Homer1 scaffolding proteins [*20,46], whose 
rare variants have been associated with autism [47]. These proteins act by modulating the physical 
link between the plasma membrane of mGlu5 and IP3R located in the endoplasmic reticulum, thus 
governing the local and global cytosolic IP3R-derived Ca2+. It is generally accepted that IP3R-
mediated Ca2+ signals in astrocytes is coupled to the release of neuroactive compounds called 
gliotransmitters [2,3,5]. The functional role of Homer1 proteins by regulating intracellular Ca2+ go 
beyond a simply permissive effect on the detection of neuronal activity. The organization of 
structural microdomains could effectively transduce specific and localized signals to tailored 
outputs, such as the release of gliotransmitters. In fact, Homer1 proteins while extering a tight 
control on Ca2+ signaling, influence astrocytic glutamate release [*20]. The existence of a mGlu5- 
and Ca2+-dependent glutamate secretion process in the developing astrocytes suggests the 
competence of astrocytes to interact with synaptic activity during assembly of synaptic circuits, as 
already reported [6,8]. It is therefore possible that glutamatergic gliotransmission plays an 
important role in the stregthening of synaptic connections and the establishment of neuronal 
pathways during post-natal development. Consistent with this idea, by manipulating secretion of 
a specific gliotransmitter, notably D-serine [48], it is possible to direct modify crucial steps of the 
development of new neurons beyond the stem or progenitor cell stage [49].  In particular, inhibition 
of vesicular release of D-serine from astrocytes in the hippocampal dentate gyrus has been reported 
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to reduce synapse formation and network integration of adult-born neurons, which in turn affect 
neuronal survival and net adult neurogenesis [49]. In addition to astrocyte-secreted 
gliotransmitters, immature astrocytes can control the formation and maturation of synaptic circuits 
by a number of secreted and contact-mediated factors [*11,12,13,14]. Despite the fact the initial 
data have been obtained mainly in culture models in vitro [50,51], the role of glial cells in the 
regulation of synapse formation and maturation of synapses has been replicated across species,  
such as in C. elegans [52], Drosophila [53], Xenopus [54], and human [55], thus indicating that 
cultured cells can be a valuable model to study the contribution of glial cells on mechanisms 
regulating synaptogenesis. 
Homer1 proteins in neurons act synergistically with SH3 and multiple ankyrin repeat domain 
proteins (Shanks) in functionally linking mGlu5 and IP3R [56,57], and the SHANK1, SHANK2 
and SHANK3 genes that encode Shank1, 2 and 3 post-synaptic scaffolding proteins are also 
expressed by astrocytes according to the recent transcriptome analysis  [18,**19]. Interestingly, 
mutations in SHANK family genes have been associated with syndromic and idiopathic ASDs and 
other neurodevelopmental disorders [56, 57,**58], and mutations in these genes in mice often give 
rise to marked behavioural phenotypes resembling those found in some human neuropsychiatric 
disorders [59]. Pharmaceutical treatments that increase mGlu5 activity ameliorate several 
behavioral deficits in mouse models of ASDs [56,57,60]. Although treatments have been 
performed in adult animals it is likely that they will show similar beneficial effects when 
administered during post-natal development. According to the recent transcriptome analysis 
SHANK 2 and 3 expression is particularly high in immature astrocytes [**19], thus suggesting that, 
like Homer1, the Shank2 and 3 coding scaffold proteins may be important in regulating post-natal 
astrocyte maturation. Given the role Homer1 and Shank proteins play in regulating cytosolic Ca2+ 
signalling, it is not surprising that alterations in the activity of this IP3R/Ca2+ signalling system 
contribute to the onset of ASDs [61,62]. The IP3R-mediated Ca2+ signalling modulated by scaffold 
proteins may be important also in the modulation of mitochondrial Ca2+ homeostasis. 
Mitochondrial Ca2+ entry of IP3R-released is mediated by a macromolecular complex composed 
by the pore forming subunit, the MCU, and several regulatory subunits including MICU1, MICU2 
and EMRE [26,27] and is a fundamental step to support oxidative phosphorylation and ATP 
production necessary for cell metabolic needs during proliferation and maturation of 
differentiating cells [63,64,65]. A fascinanting aspect surrounding mitrochondrial Ca2+ entry 
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supporting a possible involvement of this mechanism in the regulation of post-natal maturation of 
astrocytes and of associated neural circuits is the observation that human patients carrying loss-of-
function mutations in MICU1 or null mutation in MICU2 exhibit learning disability and a sever 
neurodevelopmental disorder [66,67]. 
Significant progress in our understanding of the role of astrocytes in ASDs has been made using 
mouse models of fragile X syndrome (FXS), which is caused by the transcriptional silencing of 
FMRP expression [68,69]. Astrocytes from FMR1 knock out (KO) animals induce development 
delays in the dendrite maturation of hippocampal neurons [70,71], and many studies of the same 
animals have identified an abnormal increase in mGlu5 signalling [72] that mirrors the typical 
abnormalities observed in patients with FXS [73]. Interestingly, genetic or pharmacological 
inhibition of mGlu5 activation significantly reduces the phenotypes of FMR1 KO mice [74,75], 
thus suggesting that abnormal mGlu5 signalling may contribute to the etiology of ASDs, but it is 
not clear whether mGlu5 signalling is dysregulated in developing astrocytes. However, it is likely 
that abnormal astrocyte maturation occurs in the absence of FMR1.  
Recent findings have shown the down-regulation of GLT1 expression and reduced glutamate 
uptake in the astrocytes of FMR1 KO mice during post-natal development [31]. As it is known 
that the proper expression of GLT1 is essential for normal brain development [76], it is not 
surprising that GLT1 KO mice experience severe seizures from the second post-natal week  and 
show behavioural phenotypes often observed in ASDs [77].  
 
Conclusions and perspectives 
Astrocytes have recently emerged as critical regulators of neuronal development and synapse 
formation [*11,12,13,14] and an increasing number of studies show that astrocytes are likely 
contributing to the neuronal and synaptic deficits reported in ASDs. However, despite the 
importance of the post-natal maturation of astrocytes, very little is known about the cellular and 
molecular mechanisms regulating the transition towards the mature phenotype, or the reciprocal 
mechanisms by means of which developing synapses might signal to developing astrocytes in 
order to ensure proper neural circuit formation, which therefore remain crucial challenges in the 
field. A more in depth and unbiased analysis and description of alterations/dysfunctions in 
astrocytic features during post-natal maturation of neuronal circuits will be of fundamental 
importance not only for deepening our understanding of the mechanisms governing astrocyte-
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controlled synaptogenesis, but also for developing new and unexplored therapeutic strategies for 
ASDs. 
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Fig 1. Astrocytes in the post-natal phase of development undergo dramatic molecular and 
structural changes. Genes regulating proliferation (i.e. MKI67) are progressively down-regulated 
whereas the so called “astroglial genes” (i.e. SLC1A2, Cx30 and Cx43, KCNJ10 and SLC6 coding 
for GLT1, Cx30 and 43, Kir4.1 and GABA transporter, respectively) are progressively up-
regulated. Other genes such as GRM5, FRM1, SHANK1,2,3, HOMER1 and TSP1 respectively 
coding for SHANK1,2,3, Homer1 and thrombospondin1, are also progressively down-regulated. 
During the first post-natal week astrocytes start of developing peripheral astrocyte processes that 
become progressively ramified three weeks later. Many cellular and molecular mechanisms 
regulating post-natal maturation phase of astrocytes are still to be established. 
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